DW Healthcare Partners, a healthcare-focused private equity firm, has made an investment in LKC Technologies Inc.
LKC manufactures electrophysiology testing devices to provide information on the function of the visual system. The company’s flagship product, RETeval, is a handheld electroretinography (ERG) and visual evoked potential (VEP) device used as an aid in the diagnosis and management of retina and optic nerve diseases such as diabetic retinopathy, glaucoma, and inherited retinal dystrophies.
“This partnership with DWHP is very exciting for us,” states Jim Datovech, former CEO and president at LKC. “We believe that DWHP’s experience in growing exceptional medical device companies will give us a big boost and allow our products to reach more people in need of being diagnosed before their vision issues become more serious.”